

(b) whether it is also a fact that there are more than five producers of bulk drug and more than ten formulators;

(c) whether it is also a fact that process to manufacture this drug has been developed indigenously; and

(d) whether this drug will be price decontrolled?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Sales turn over of formulations is not monitored.

(c) and (d) Applications received from various companies seeking exemption of different bulk drugs from price control on this ground are under consideration.

Price control on Paracetamol

1451. SHRI BEKAL UTSAHI; Will the Minister of INDUSTRY, be pleased to refer to the answer to Unstarred Question 140 given in the Rajya Sabha on the 24th April, 1989 and state:

(a) whether it is a fact that Paracetamol fulfils all the exclusion criteria;

(b) whether it is also a fact that none of the formulators account for turnover of more than 23 per cent;

(c) whether his Ministry has examined the comparison of concentration of Paracetamol to Glybenclomide;

(d) if so, what are the details thereof; and

(e) what steps have been taken by his Ministry to rectify these discrepancies?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) After considering various representations, the Kelkar Committee, in its Supplementary Report, has recommended Shifting of Paracetamol from Schedule I of DPCO, 1987 to Schedule II and exemption of Glybenclamide from price control under

DPCO 1987. These recommendations of the Kelkar Committee have been accepted by the Government.

Price of Aspirin.

1452. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) when were the recommendations regarding fair price of Aspirin received from SICP;

(b) when was the price fixed by his Ministry;

(c) whether his Ministry fixed any ad hoc price;

(d) if so, on whose recommendations; and

(e) what are the reasons for not referring the matter of fixation of ad hoc price to BICP?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The price of Aspirin bulk drug was revised to Rs. 80/- per kg. on "ad hoc" basis with effect from 2.6.1988 consequent on the representations received from the manufacturers of this drug. However, the Cost Price study of this drug was simultaneously taken up by the BICP and on the basis of BICP Report received in November 1988 a Price of Rs. 71/- per kg. has been fixed with effect from 20.1.1989 on their recommendations.

Price control on Vitamin B6

1453. SHRI M. KADHARSHA; Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Vitamin B6 is being produced from intermediate stage by certain producers;

(b) what are the names, of producers of Vitamin B6 and what is the stage of production of each;

(c) whether it is a fact that import contents in the production from intermediate stage is more than the CIF price of the imported drug;

(d) what are the imported intermediates used by the companies and what is the import content per kg. of production of Vitamin B6;

(e) whether it is a fact that Vitamin B6 is price decontrolled; and

(f) if so, what steps have been taken to rectify the situation?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Two companies namely M/s. IDPL and M/s. Lupin Lab Ltd., are producing Vit. B6 bulk drug from DL-Alanine and Ethyl Aceto Acetate Stage respectively.

(c) and (d) The CIF price of Vit. B6 ranges from US \$ 35.00 to 40.00 (around Rs. 540 to Rs. 620 per kg.) whereas as per the information received from the Companies, the CIF price for imported raw materials going into the production of 1 kg. of Vit. B6 is approximately Rs. 212 for M/s. IDPL and Rs. 204.34 for M/s. Lupin Labs Ltd.

Both the companies are using four imported raw materials as per details given below:-

M/s. IDPL

1. DL-Alanine
2. Disbutenediol
3. Dimethyl Formamide.
4. Isobutyraldehyde

M/s. Lupin • lab limited

1. Ethyl Aceto Acetate
2. Formamide.
3. Butenediol
4. Isobutyraldehyde.

(e) Yes, Sir.

(f) Does not arise, in view of information at (c) and (d) above.

Concentration aspect in the Kelkar Committee Report

1454. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the Kelkar Committee has not defined concentration in the Report;

(b) what is the meaning of concentration as adopted by the Committee;

(c) whether his Ministry has examined the criteria of concentration and its meaning;

(d) whether it is also a fact that concentration aspect has been ignored in several instances;

(e) whether his Ministry has come across such instances; and

(f) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) The relevant papers are being looked into and information, to the extent available, will be laid on the Table of the House, as early as possible.

Shifting of Rifampicin from Category-I to Category-II

1455. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state;

(a) whether it is a fact that Kelkar Committee observed cartel formulation in the import of intermediate as well as bulk drug while recommending shifting of Rifampicin from Category-I to Category-II;

(b) whether it is a fact that committee discussed to allow free imports of both to prevent cartel formulation;

(c) whether Committee made any recommendations in respect to free imports and overinvoicing; and